GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Sale Of Business

TuHURA Biosciences (TuHURA Biosciences) Sale Of Business : $ Mil (TTM As of Dec. 2022)


View and export this data going back to 2050. Start your Free Trial

What is TuHURA Biosciences Sale Of Business?

TuHURA Biosciences's sale of business for the six months ended in Dec. 2022 was $0.00 Mil. It means TuHURA Biosciences gained $0.00 Mil from selling business. TuHURA Biosciences does not have enough years/quarters to calculate the sale of business for the trailing twelve months (TTM) ended in Dec. 2022.

Compared with last quarter ($0.00 Mil in Dec. 2021 ), TuHURA Biosciences gained the same money from selling business in Dec. 2022 ($0.00 Mil).


TuHURA Biosciences Sale Of Business Historical Data

The historical data trend for TuHURA Biosciences's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Sale Of Business Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22
Sale Of Business
- -

TuHURA Biosciences Semi-Annual Data
Dec21 Dec22
Sale Of Business - -

TuHURA Biosciences Sale Of Business Calculation

The amount earned to sell business.



TuHURA Biosciences Sale Of Business Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


TuHURA Biosciences (TuHURA Biosciences) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
Website
TuHURA Biosciences Inc is a clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies. The company's lead personalized cancer vaccine candidate, IFx-Hu2.0, is designed to prime the activation of the immune system to target and attack tumor cells by making them look like bacteria. Through an intratumoral injection of a gene coding for emm55, an immunogenic bacterial protein that is then expressed on the surface of tumor cells, the immune system is activated, providing a potent, multivalent systemic response against all neoantigens in a patient's tumor.

TuHURA Biosciences (TuHURA Biosciences) Headlines

No Headlines